Patient Centered Care

Exploring Gene and Cell Therapy Integration in Pharmacies

January 29, 2024 - After seeing promising results in cell and gene therapy clinical trials, cell and gene therapy is transforming patient care, offering new possibilities for treating diseases that previously had limited treatment options. As pharmacies integrate these therapies into their operations, they face challenges and opportunities. In a recent conversation with Tracey James, RPh, Chief Operating...

Read More


More Articles

Optimizing Cancer Care Pathways Through Precision Medicine, RWD

by Editorial Staff

Personalized medicine is vital because it streamlines clinical decision-making through genetic tests or biomarkers. Essentially, personalized care lets caregivers feel more confident that a patient will respond to a specific drug or be...

Exploring Prescription Discount Cards’ Role in Medication Adherence

by Editorial Staff

Since prescription discount cards were introduced into the United States market in the early 2000s, patients and providers have leveraged them to combat rising drug costs and make medications more affordable. By enhancing drug...

How Medical Affairs Impact the Pharmaceutical Industry

by Editorial Staff

Nearly every medical device or pharmaceutical company has a medical affairs team responsible for gathering scientific data and communicating it with leaders in the pharmaceutical industry. However, a...

Effectively Managing Clinical Trials, Recruitment, and Adaptive Trials

by Veronica Salib

Clinical trial significance and success throughout the COVID-19 pandemic have inspired the launch of clinical trial branches for existing companies, such as Walgreens, and multiple startups. However, it is critical to note that while some...

Prescription Drug Manufacturer Pre-Rebate Costs Skyrocket

by Samantha McGrail

From 2015 to 2019, median prescription drug manufacturer pre-rebate costs per covered life (PCL) increased by 68.1% for individual plans, 44.9% for small group plans, and 23.9% for large group plans,...

FDA Approves Eli Lilly and Company’s Type 2 Diabetes Injectable

by Samantha McGrail

FDA recently approved Eli Lilly and Company’s Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes as an addition to diet and...

Roche, Global Fund to Build Diagnostic Capacity of HIV, Tuberculosis

by Samantha McGrail

Roche’s Global Access Program and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, recently partnered to build and strengthen diagnostic capacity and pandemic preparedness in...

J&J Appoints Thibaut Mongon CEO of New Consumer Health Company

by Samantha McGrail

Johnson & Johnson recently appointed Thibaut Mongon as chief executive officer and Paul Ruh as chief financial officer designate of its future consumer health company.   With over 20...

Novo Nordisk, Flagship to Develop Rare Disease Treatments

by Samantha McGrail

Novo Nordisk and Flagship Pioneering recently collaborated to create a portfolio of novel research programs to develop transformation metabolic and rare disease treatments. The companies will apply...

Gilead, Dragonfly to Advance Immunotherapies in Oncology

by Samantha McGrail

Gilead and Dragonfly Therapeutics recently collaborated to advance several of Dragonfly’s novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation...

J&J Launches Satellite Center to Tackle Antimicrobial Resistance

by Samantha McGrail

Johnson & Johnson recently launched the J&J Satellite Center for Global Health Discovery (Satellite Center) to tackle the present and the rising threat of antimicrobial resistance (AMR) with a...

FDA Considers New Strategy to Boost Safe Opioid Disposal

by Samantha McGrail

FDA is seeking public comment on a potential change that would require opioid analgesics used in outpatient settings to be dispensed with prepaid mail-back envelopes and that pharmacies provide patient...

GSK Enters $1.9B Agreement to Develop Rare Cancer Treatments

by Samantha McGrail

GSK recently entered into a $1.9 billion agreement to acquire biopharmaceutical company Sierra Oncology to treat rare cancers.   Myelofibrosis is a rare blood cancer that causes considerable...

FDA Lifts Hold on Gilead’s MDS, AML Clinical Trials

by Samantha McGrail

FDA recently lifted the partial hold placed on clinical trials evaluating Gilead’s magrolimab combined with azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)...

FDA Issues Draft Guidance to Increase Clinical Trial Diversity

by Samantha McGrail

FDA recently issued draft guidance to enroll more participants from underrepresented racial and ethnic populations in the United States into trials, expanding overall clinical trial...

Pfizer to Acquire BioPharma Company to Develop RSV Therapeutics

by Samantha McGrail

Pfizer will acquire clinical-stage biopharmaceutical company ReViral to discover, develop, and commercialize novel antiviral respiratory syncytial virus (RSV) therapeutics.   ReViral’s...

New Toolkit Supports Digital Endpoints in Drug Development

by Samantha McGrail

The Digital Medicine Society (DiMe), Anthem, Biogen, Eli Lilly & Company, Evidation, Janssen, Merck, Pfizer, and Savvy Co-op recently launched a toolkit of resources to support organizations...

AstraZeneca to Share New Data on Oncology Treatment Landscape

by Samantha McGrail

AstraZeneca recently announced that it will present new data underscoring its oncology treatment landscape through diverse early pipelines and novel drug combinations.  The company’s next...

Gilead Grants $24M to Improve Access, Care for HIV Communities

by Samantha McGrail

Gilead recently announced $24 million in grants to reduce health disparities, improve access to quality healthcare, advance medical education, and support local communities most impacted by the HIV and...

Recent Articles